FDA lifts bar for Sun at its key Halol plant
Executive Summary
Sun Pharma can finally begin to receive US Food and Drug Administration (FDA) approvals for new products from its key Halol formulations manufacturing facility in Gujarat, India, after successfully addressing all issues in a longstanding warning.
You may also be interested in...
Sun Grapples With Impact Of Halol FDA Import Alert
Sun Pharma’s Halol facility has been placed under an import alert by the FDA following an inspection earlier this year that uncovered GMP deficiencies.
Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites
An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.
Sun Pharma Commits To Generic Investment But Admits It Is Not Attractive In Current Environment
Sun’s MD Dilip Shanghvi made the rather frank admission during the firm’s third-quarter earnings call, maintaining that generics is nevertheless an “interesting” business for the Indian major. In light of this outlook, Sun has continued its policy of withdrawing what it feels are “unviable” ANDAs from under FDA review.